Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)

v3.19.3
Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-In Capital [Member]
Subscription Receivable [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2017 $ 3,527 $ 4,228,723 $ (3,859,086) $ 373,164
Balance, shares at Dec. 31, 2017 35,272,626        
Recognize the fair value of exclusive license intangible asset acquired from CoNCERT in exchange for 2,090,301 common shares of Processa held by Promet 8,000,000 8,000,000
Net loss (1,096,798) (1,096,798)
Balance at Mar. 31, 2018 $ 3,527 12,228,723 (4,955,884) 7,276,366
Balance, shares at Mar. 31, 2018 35,272,626        
Balance at Dec. 31, 2017 $ 3,527 4,228,723 (3,859,086) 373,164
Balance, shares at Dec. 31, 2017 35,272,626        
Net loss         (3,155,874)
Balance at Sep. 30, 2018 $ 3,867 19,317,036 (1,800,000) (7,014,961) 10,505,942
Balance, shares at Sep. 30, 2018 38,674,265        
Balance at Mar. 31, 2018 $ 3,527 12,228,723 (4,955,884) 7,276,366
Balance, shares at Mar. 31, 2018 35,272,626        
Conversion of Senior convertible notes for common stock and stock purchase warrants $ 121 2,390,248 2,390,369
Conversion of Senior convertible notes for common stock and stock purchase warrants, shares 1,206,245        
Issuance of common stock units for cash, net of costs of $218,422 $ 140 2,964,955 2,965,095
Issuance of common stock units for cash, net of costs of $218,422, shares 1,402,442        
Issuance of common stock units for a future research funding commitment, net of costs of $117,339 $ 79 1,682,582 (1,800,000) (117,339)
Issuance of common stock units for a future research funding commitment, net of costs of $117,339, shares 792,952        
Net loss (1,206,255) (1,206,255)
Balance at Jun. 30, 2018 $ 3,867 19,266,508 (1,800,000) (6,162,139) 11,308,236
Balance, shares at Jun. 30, 2018 38,674,265        
Stock-based compensation 50,528 50,528
Net loss (852,822) (852,822)
Balance at Sep. 30, 2018 $ 3,867 19,317,036 (1,800,000) (7,014,961) 10,505,942
Balance, shares at Sep. 30, 2018 38,674,265        
Balance at Dec. 31, 2018 $ 3,867 19,121,285 (1,800,000) (7,624,134) 9,701,018
Balance, shares at Dec. 31, 2018 38,674,265        
Stock-based compensation 58,559 58,559
Payments made by investor for clinical trial costs 115,000 115,000
Net loss (750,832) (750,832)
Balance at Mar. 31, 2019 $ 3,867 19,179,844 (1,685,000) (8,374,966) 9,123,745
Balance, shares at Mar. 31, 2019 38,674,265        
Balance at Dec. 31, 2018 $ 3,867 19,121,285 (1,800,000) (7,624,134) 9,701,018
Balance, shares at Dec. 31, 2018 38,674,265        
Net loss         (2,583,433)
Balance at Sep. 30, 2019 $ 3,840 18,874,406 (10,207,567) 8,670,679
Balance, shares at Sep. 30, 2019 38,404,530        
Balance at Mar. 31, 2019 $ 3,867 19,179,844 (1,685,000) (8,374,966) 9,123,745
Balance, shares at Mar. 31, 2019 38,674,265        
Stock-based compensation 66,476 66,476
Payments made by investor for clinical trial costs 280,927 280,927
Net loss (969,077) (969,077)
Balance at Jun. 30, 2019 $ 3,867 19,246,320 (1,404,073) (9,344,043) 8,502,071
Balance, shares at Jun. 30, 2019 38,674,265        
Conversion of Senior convertible notes for common stock and stock purchase warrants $ 13 258,917 258,930
Conversion of Senior convertible notes for common stock and stock purchase warrants, shares 126,741        
Stock-based compensation 269,129 269,129
Payments made by investor for clinical trial costs 504,073 504,073
Pledged shares of common stock forfeited upon revised research funding commitment $ (40) (899,960) 900,000
Pledged shares of common stock forfeited upon revised research funding commitment, shares (396,476)        
Net loss (863,524) (863,524)
Balance at Sep. 30, 2019 $ 3,840 $ 18,874,406 $ (10,207,567) $ 8,670,679
Balance, shares at Sep. 30, 2019 38,404,530